MicroPort® Orthopedics Aspiration Medial Stability Total Knee Replacement System – PS Type Implant Obtains Approval in China


Shanghai, China – Suzhou MicroPort Joint MedTech Co., Ltd, which is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), obtained the registration certificate for Aspiration Medial Stability Total Knee Replacement System – PS Type Implant from National Medical Products Administration of China (NMPA) on January 9. It is the first approval granted for MicroPort® Orthopedics' domestically manufactured total knee replacement system, which will bring a more comprehensive total knee replacement solution to the Chinese patients suffering from degenerative knee diseases and provide the surgeons with more product offerings.
With a rapidly aging population growth and significant improvement in people's living standard, the incidence rate of degenerative knee diseases is gradually increasing. Statistics show that the number of total knee replacements is expected to total 400,000 cases in China by 2020. However, some researches indicated that nearly 20% of patients were not satisfied with the effect of traditional total knee replacement, mainly due to post-operative knee instability. The Aspiration Medial Stability Total Knee Replacement System – PS Type Implant combined the post-cam design of PS implant and the unique and innovative highly bionic medial stabilized ball-in-socket design of MicroPort® Orthopedics. It not only provides a wider range of joint motion and more reliable wear resistance, but also restores the kinematics of normal knees and maintains their stability in motion, which makes the post-operative kinematic features and patients' gaits more natural. As a result, the patients' satisfaction level will become higher.
Since 1998, the MicroPort® first generation medial pivot TKA has been marketed in the United States. With 20 years of successful clinical results and over 600,000 cases globally, medial pivot knee announced its excellent implant survivorship (98.8%) and patient satisfaction(95%) over 17 years follow-up. MicroPort® patented unique innovative medial pivot system features a ball-in-socket joint design, which is established on a clinically approved successful design. With the stability at the medial side and the balanced movement at the lateral side, the mechanics and kinematics of normal knee can be restored. As a result, the patients feel more comfortable and almost have a "forgotten" knee.
MicroPort® Orthopedics China President Robin Weng said, "The approval of the first domestically manufactured Aspiration total knee replacement system marks an additional improvement in MicroPort® Orthopedics' product portfolio of domestically made joints. We will always adhere to the MicroPort® mission of 'Innovating relentlessly to commercialize the best yet affordable therapeutic solutions to save, reshape or improve the patients' lives', and commit to the R&D and promotion of new techniques, rationales and products in the field of orthopedics, so as to have more Chinese patients benefit from our best yet affordable therapeutic solutions."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs MicroPort Scientific Corporation
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com